| Literature DB >> 27913856 |
Pradesh Kumar1, Rajeev Ravi2, Gaurav Sundar2, Caroline Shiach3.
Abstract
The direct oral anticoagulants (DOACs) have emerged as a good alternative for the treatment of thromboembolic diseases, and their use in clinical practice is increasing rapidly. The DOACs act by blocking the activity of one single step in the coagulation cascade. These drugs act downstream in the common pathway of the coagulation cascade by directly antagonising the action of thrombin or factor Xa. The development of DOACs represents a paradigm shift from the oral vitamin K antagonists such as warfarin. This article aims to describe the properties of the currently available DOACs including pharmacology and dosing. We also address the strategies for periprocedural management and reversal of anticoagulation of patients treated with these agents.Entities:
Keywords: Anticoagulation; Bleeding; Direct oral anticoagulants; Periprocedural
Mesh:
Substances:
Year: 2016 PMID: 27913856 DOI: 10.1007/s00270-016-1521-0
Source DB: PubMed Journal: Cardiovasc Intervent Radiol ISSN: 0174-1551 Impact factor: 2.740